Prof Stricker, the chief investigator on the current Active Surveillance trial, said that the trial is running extremely well and accruing valuable data rapidly.
This trial is to assess the role of MRI in monitoring patients on active surveillance instead of using the traditional technique of biopsy. Biopsies will be used but much less often. This trial will involve 300 patients and already over a 100 have accrued to this trial. In addition to this, Prof Stricker will be using various genetic testing to further identify patients who are suitable for active surveillance.